Genzyme Corporation
Cambridge, MA Doing business as Sanofi Genzyme
- UEI
- X2XMAQLR9DA8
- CAGE
- 1HBD8
- Primary NAICS
- 325412 Pharmaceutical Preparation Manufacturing
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- Other NAICS codes in SAM.gov
- Corporate family
-
-
- FDGZE5FX6M43
-
- SAM.gov registration date
- Physical address
- 450 Water St, Cambridge, MA 02141, USA
- Website
- sanofi.com
- Founded
- 1973
- Employees
- 50K-100K
- Estimated annual revenue
- $10B+
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2027 To date | $0 |
| FY2026 | $0 |
| FY2025 | -$14,636 |
| FY2024 | -$84,754 |
| FY2023 | $731,715 |
Contract vehicles
Contract awards
Latest 5 listed here. See the rest on GovTribe.
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Cipla USA Inc. | — | 424210 Drugs and Druggists' Sundries Merchant Wholesalers |
| TG Therapeutics Inc. | Morrisville, NC | 325412 Pharmaceutical Preparation Manufacturing |
| Astellas Pharma US, Inc. | Northbrook, IL | 325412 Pharmaceutical Preparation Manufacturing |
| Mylan Pharmaceuticals Inc. | Morgantown, WV | 325412 Pharmaceutical Preparation Manufacturing |
| Ascendis Pharma, Inc. | — | 325412 Pharmaceutical Preparation Manufacturing |
About the company
Genzyme Corporation Sanofi Genzyme Division, doing business as Sanofi Genzyme, is a global healthcare and pharmaceutical company dedicated to improving people's lives through innovative scientific advancements. It provides pharmaceuticals and drugs to federal agencies, primarily the Department of Veterans Affairs (VA) Veterans Health Administration (VHA), through its Pharmaceuticals and Drugs GSA Schedule contract (FSS-61-IB).
Genzyme Corporation has received numerous firm fixed price delivery orders under the Pharmaceuticals and Drugs GSA Schedule from various VHA Networks (VISNs) and medical centers nationwide. The orders have been for specialty pharmaceutical products like Eliglustat (Cerdelga), Lemtrada, Caprelsa (vandetanib), and other cancer drugs to support treatment programs for veterans. Genzyme typically serves as the prime contractor, with no set-aside designations applied. Orders range from emergency pharmaceutical procurements to fulfill immediate needs to larger bulk purchases of medication, with performance periods spanning weeks to over a year. Deliveries are made to VA medical facilities across the country from Genzyme's places of performance in locations like Cambridge, MA and Riverwoods, IL.
Genzyme Corporation holds two major federal contract IDVs for pharmaceuticals. The first is a $659 million multiple award Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) with VA providing the ability to issue task orders for a broad range of drugs and products over a 5-year period. Genzyme has been awarded numerous delivery orders against this vehicle by VHA Networks for specialty medications. Additionally, Genzyme has a $4 million single-award BPA from the VA National Acquisition Center specifically for Lemtrada and Cerdelga, providing a streamlined contracting method for these drug products over 5 years. Genzyme's IDVs allow federal healthcare agencies efficient access to its pharmaceutical product portfolio to support their programs serving veterans, military members, and other patients.
Quick answers
Is Genzyme Corporation registered in SAM.gov?
Yes. Genzyme Corporation's SAM.gov registration is active through May 8, 2027.
Which contract vehicles does Genzyme Corporation hold?
Genzyme Corporation holds a place on 1 federal contract vehicle: FSS-61-IB.
How much has Genzyme Corporation received in federal contracts?
Federal contracts obligated $632,325 to Genzyme Corporation in fiscal years 2023 through 2027.
What is Genzyme Corporation's most recent federal award?
Genzyme Corporation's most recent federal contract award is Caprelsa 100MG (36C26124N0260), from Veterans Integrated Service Network 21 (VHA), on November 20, 2023.
On GovTribe
See Genzyme Corporation's full federal record
- Federal contract awards
- IDV awards
- Contract vehicles
- Funding analysis by agency, NAICS and set-aside
- Similar vendors